在阿尔茨海默氏症治疗中探索双金属纳米粒子:一种具有多目标潜力的新型生物辅助合成
Gülcihan Gülseren1,2, Zeynep Demirsoy2, Merve Şeker2
1Department of Molecular Biology and Genetics, Konya Food and Agriculture University, Konya 42080, Turkey.
Molecular pharmaceutics
|May 2, 2024
概括
使用纳米纤维合成的新双金属金/银纳米颗粒 (Au/Ag-NPs) 显示出对阿尔茨海默病治疗的重大前景. 这些纳米颗粒有效地抑制了粉样β聚合,并减少了氧化应激,提供了多目标治疗方法.
科学领域:
- 纳米技术和材料科学 材料科学
- 生物医学工程 生物医学工程
- 神经科学是一个神经科学.
背景情况:
- 金属纳米粒子 (NPs),特别是金 (AuNPs) 和银 (AgNPs),显示出治疗神经退行性疾病 (如阿尔茨海默氏症) 的潜力.
- 双金属Au/Ag-NP具有协同作用的潜力,但由于传统方法的合成,生物相容性和多功能性受到限制.
- 生物基合成提供了一种创新的解决方案,以克服这些局限性并提高NP的治疗疗效.
研究的目的:
- 开发一种新的基于生物的合成双金属Au/Ag-NP使用原仿真纳米纤维.
- 评估这些绿色双金属NP在抑制粉样β (Aβ) 聚合中的有效性.
- 评估Au/Ag-NP对抗阿尔茨海默病特征的多目标治疗潜力,包括酶抑制和活性氧物种 (ROS) 减少.
主要方法:
- 合成双金属金/银纳米颗粒 (Au/Ag-NPs) 使用原模仿纳米纤维作为生物活性模板.
- 与单个AuNP和AgNP相比,Aβ蛋白聚合抑制的评估.
- 对雌激酶和活性氧物种 (ROS) 的抑制活性评估.
主要成果:
- 合成的绿色Au/Ag-NP显著抑制了Aβ聚合 (74%),表现优于单个AuNP (66%) 和AgNP (43%).
- 双金属Au/Ag-NP对雌激酶 (∼50%) 和ROS (∼75%) 具有显著的抑制活性.
- Au/Ag-NPs显示了增强的细胞屏障透,3D吸收和内体体逃生能力.
结论:
- 使用类纳米纤维生物合成的双金属Au/Ag-NP代表了阿尔茨海默病的有前途的多目标治疗策略.
- 这些NP提供了机械效益,包括Aβ和乙胆酶 (AChE) 抑制,ROS降低和改善细胞内化.
- 这项研究推动了神经退行性疾病的新型治疗方法的开发,超越了对单金属纳米颗粒的关注.
更多相关视频
11:28Biofunctionalized Prussian Blue Nanoparticles for Multimodal Molecular Imaging Applications
Published on: April 28, 2015
10.4K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.9K
相关概念视频
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
